Aprepitant is used as:
**Core Concept**
Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist used in the management of chemotherapy-induced nausea and vomiting (CINV). It works by blocking the action of substance P, a neurotransmitter involved in the transmission of nausea and vomiting signals from the central nervous system to the vomiting center in the brain.
**Why the Correct Answer is Right**
Aprepitant is administered orally or intravenously and is typically used in combination with other antiemetics, such as 5-HT3 antagonists and corticosteroids, to prevent CINV. By blocking the NK1 receptors in the central nervous system, aprepitant reduces the release of substance P, leading to a decrease in the emetic response. This results in improved control of nausea and vomiting in patients receiving chemotherapy.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because aprepitant is not a dopamine D2 receptor antagonist, which is a different class of antiemetics used to treat CINV.
**Option B:** This option is incorrect because aprepitant is not a corticosteroid, which is used to reduce inflammation and has antiemetic effects through a different mechanism.
**Option C:** This option is incorrect because aprepitant is not a 5-HT3 receptor antagonist, which is another class of antiemetics used to treat CINV.
**Clinical Pearl / High-Yield Fact**
Aprepitant is an important addition to the antiemetic regimen for chemotherapy-induced nausea and vomiting, particularly in patients receiving highly emetogenic chemotherapy agents. Its use has been shown to improve patient outcomes and reduce the need for rescue antiemetics.
**Correct Answer:** D (Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist used in the management of chemotherapy-induced nausea and vomiting (CINV).)